A Part of the University of Maryland Medical Center

Connect with UMGCC
Facebook Twitter YouTube Blog iPhone
Email PageEmail page Print PagePrint page

Researcher Information

Kevin J. Cullen, M.D.
Director, University of Maryland
Greenebaum Cancer Center

Professor of Medicine

Department:
University of Maryland Marlene and Stewart Greenebaum Cancer Center

UMGCC Research Program:
Experimental Therapeutics Program

Education/Training:
College Degree: B.A., Cum Laude, Dartmouth College, Hanover, NH
Medical Degree: Harvard Medical School, Boston, MA
Residency: Beth Israel Medical Center, Boston, MA
Fellowship: National Cancer Institute, NIH, Bethesda, MD
Certification: Medical Oncology, Internal Medicine

Contact Information:

Mailing Address: University of Maryland
Greenebaum Cancer Center
22 South Greene Street
Baltimore, MD, 21201
Email: kcullen@umm.edu
Phone: 410-328-5506
Fax: 410-328-8455

Research Interests:
Dr. Kevin Cullen's laboratory examines mechanisms of chemotherapy resistance in head and neck cancer. Specifically, his group has demonstrated that specific biochemical markers, especially enzymes related to the glutathione pathway, are important predictors of response to cisplatin based chemotherapy in head and neck tumors and that those same markers also predict prognosis. Elevated cellular glutathione is associated with decreased formation of cisplatin/DNA adducts and resistance to that class of drugs. Recently, Dr. Cullen's group has investigated the issue of disparities based on ethnicity and race in head and neck cancer. His team was the first to describe that survival disparities in head and neck cancer between blacks and whites is explained in significant part by differences in the rate of human papilloma virus infection in those two groups. Dr. Cullen is funded for this research through NCI and industrial collaborations.

Publications:

Scheper MA, Badros A, Salama AR, Warburton G, Cullen KJ, Weikel DS, Meiller TF. A novel bioassay model to determine clinically significant bisphosphonate levels. Support Care Cancer, Dec;17(12):1553-7, 2009.

Settle K, Taylor R, Wolf J, Kwok Y, Cullen K, Carter K, Ord R, Zimrin A, Strome S, Suntharalingam M. Race impacts outcome in stage III/IV squamous cell carcinomas of the head and neck after concurrent chemoradiation therapy. Cancer, Apr 15;115(8):1744-52, 2009.

Posner MR, Norris CM, Wirth LJ, Shin DM, Cullen KJ, Winquist EW, Blajman CR, Mickiewicz EA, Frenette GP, Plinar LF, Cohen RB, Steinbrenner LM, Freue JM, Gorbunova VA, Tjulandin SA, Raez LE, Adkins DR, Tishler RB, Roessner MR, Haddad RI; for the TAX 324 Study Group. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol, May;20(5):921-7, 2009.

Cullen KJ, Schumaker L, Nikitakis N, Goloubeva O, Tan M, Sarlis NJ, Haddad RI, Posner, MR. ²-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck. A companion analysis of the TAX 324 Trial. J Clin Oncol., 27(36): 6222-6228, 2009.

Settle K, Posner MR, Schumaker L, Tan M, Suntharaligam M, Goloubeva O, Strome SE, Haddad RI, Patel SS, Cambell EV,III, Sarlis N, Lorch J, and Cullen KJ.. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prevention Res, 2: 776-781, 2009.

Yovino S, Settle K, Taylor R, Wolf J, Kwok Y, Cullen K, Ord R, Zimrin A, Strome S, Suntharalingam M. Patterns of failure among patients with squamous cell carcinoma of the head and neck who obtain a complete response to chemoradiotherapy. Head Neck. 32(1):46-52, Jan 2010.

Rutter CE, Yovino S, Taylor R, Wolf J, Cullen KJ, Ord R, Athas M, Zimrin A, Strome S, Suntharalingam M. Impact of early percutaneous endoscopic gastrostomy tube placement on nutritional status and hospitalization in patients with head and neck cancer receiving definitive chemoradiation therapy. Head & Neck, 33: n/a. doi: 10.1002/hed.21624, Dec 2010.

Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, Haddad RI, Cullen KJ. Survival and human papillomavirus in oropharynx cancer in tax 324: a subset analysis from an international phase III trial. Annals of Oncology, 22(5):1071-7, May 2011.

Scheper M, Chaisuparat R, Cullen K, Meiller T. A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis. Fibrogenesis Tissue Repair, 1;3:6. Apr 2011.

Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR; TAX 324 Study Group. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol, 12(2):153-9, Feb 2011.

Strongin A, Yovino S, Taylor R, Wolf J, Cullen K, Zimrin A, Strome S, Regine W, Suntharalingam M. Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys, May 5, 2011.

Suntharalingam M, Kwok Y, Goloubeva O, Parekh A, Taylor R, Wolf J, Zimrin A, Strome S, Ord R, Cullen KJ. Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys, May 19, 2011.

Wu Y, Posner MR, Schumaker LM, Nikitakis N, Goloubeva O, Tan M, Lu C, Iqbal S, Lorch J, Sarlis NJ, Haddad RI, Cullen KJ. Novel biomarker panel predicts prognosis in HPV-negative oropharyngeal cancer: An analysis of the TAX 324 trial. Cancer: A Journal of the American Cancer Society, In Press, 2011.